Profile data is unavailable for this security.
About the company
2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.
- Revenue in USD (TTM)44.12m
- Net income in USD-156.25m
- Incorporated2021
- Employees274.00
- Location2Seventy Bio Inc60 Binney StreetCAMBRIDGE 02210United StatesUSA
- Phone+1 (339) 499-9300
- Fax+1 (302) 636-5454
- Websitehttps://www.2seventybio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XBiotech Inc | 0.00 | -35.01m | 230.00m | 94.00 | -- | 1.17 | -- | -- | -1.15 | -1.15 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -15.53 | 31.88 | -16.32 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0484 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Onkure Therapeutics Inc | 0.00 | -56.54m | 234.51m | 8.00 | -- | 0.7643 | -- | -- | -16.82 | -16.82 | 0.00 | 23.00 | 0.00 | -- | -- | 0.00 | -49.87 | -- | -53.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -102.44m | 234.53m | 88.00 | -- | 1.37 | -- | -- | -3.04 | -3.04 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -51.66 | -49.99 | -57.25 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0081 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Enanta Pharmaceuticals Inc | 71.96m | -115.33m | 234.56m | 145.00 | -- | 1.57 | -- | 3.26 | -5.46 | -5.46 | 3.41 | 7.03 | 0.161 | -- | 5.32 | 496,275.90 | -25.80 | -14.56 | -30.05 | -15.62 | -- | -- | -160.27 | -54.96 | -- | -- | 0.0095 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Amarin Corporation plc (ADR) | 241.02m | -39.35m | 236.44m | 275.00 | -- | 0.4449 | -- | 0.981 | -0.0959 | -0.0959 | 0.5876 | 1.29 | 0.3032 | 0.4387 | 2.05 | 876,440.00 | -4.95 | -4.48 | -7.02 | -6.54 | 56.46 | 75.70 | -16.32 | -8.59 | 2.11 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| aTyr Pharma Inc | 588.00k | -57.90m | 236.48m | 56.00 | -- | 2.90 | -- | 402.18 | -0.9047 | -0.9047 | 0.0092 | 1.08 | 0.0049 | -- | 0.4034 | 10,500.00 | -48.51 | -45.45 | -53.89 | -52.74 | -- | -- | -9,846.26 | -784.19 | -- | -- | 0.0202 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Caribou Biosciences Inc | 11.48m | -148.12m | 242.68m | 158.00 | -- | 0.863 | -- | 21.15 | -1.65 | -1.65 | 0.128 | 3.11 | 0.0286 | -- | 5.08 | 72,626.59 | -36.94 | -- | -39.76 | -- | -- | -- | -1,290.81 | -- | -- | -1,321.46 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| 2Seventy Bio Inc | 44.12m | -156.25m | 243.59m | 274.00 | -- | 1.04 | -- | 5.52 | -3.06 | -3.06 | 0.8417 | 4.56 | 0.0721 | -- | 1.42 | 161,021.90 | -25.54 | -- | -28.17 | -- | 66.39 | 91.76 | -354.16 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Compass Therapeutics Inc. | 850.00k | -47.24m | 247.66m | 32.00 | -- | 1.70 | -- | 291.37 | -0.3573 | -0.3573 | 0.0064 | 1.06 | 0.0051 | -- | -- | 26,562.50 | -28.22 | -41.75 | -29.94 | -46.41 | -- | -- | -5,557.88 | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Climb Bio Inc | 0.00 | -64.20m | 254.16m | 9.00 | -- | 1.14 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Omeros Corp | 0.00 | -199.92m | 255.55m | 198.00 | -- | -- | -- | -- | -3.32 | -2.35 | 0.00 | -2.15 | 0.00 | -- | -- | 0.00 | -45.24 | -55.51 | -58.74 | -70.10 | -- | -- | -- | -- | -- | -5.74 | 1.42 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Editas Medicine Inc | 61.76m | -210.57m | 257.55m | 265.00 | -- | 1.47 | -- | 4.17 | -2.56 | -2.56 | 0.752 | 2.13 | 0.1484 | -- | 48.48 | 233,049.10 | -50.61 | -29.85 | -60.06 | -33.19 | -- | -- | -340.96 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Nektar Therapeutics | 93.16m | -177.08m | 257.71m | 137.00 | -- | 3.23 | -- | 2.77 | -0.9007 | -0.9007 | 0.4747 | 0.4329 | 0.2224 | 2.16 | 73.61 | 679,978.10 | -42.28 | -31.02 | -48.54 | -34.63 | 59.22 | 78.04 | -190.09 | -372.21 | 4.90 | -18.76 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Personalis Inc | 87.49m | -91.44m | 257.97m | 223.00 | -- | 1.93 | -- | 2.95 | -1.68 | -1.68 | 1.64 | 2.36 | 0.3751 | 7.18 | 6.45 | 392,327.30 | -39.20 | -28.84 | -45.99 | -34.72 | 31.41 | 28.65 | -104.52 | -96.01 | 4.44 | -- | 0.0098 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
Data as of Nov 08 2024. Currency figures normalised to 2Seventy Bio Inc's reporting currency: US Dollar USD
57.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kynam Capital Management LPas of 30 Jun 2024 | 5.95m | 11.56% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 4.09m | 7.95% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 3.59m | 6.96% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.26m | 6.33% |
| Madison Avenue Partners LPas of 30 Jun 2024 | 2.56m | 4.98% |
| Baker Bros. Advisors LPas of 30 Jun 2024 | 2.50m | 4.85% |
| Newtyn Management LLCas of 30 Jun 2024 | 2.49m | 4.83% |
| Casdin Capital LLCas of 30 Jun 2024 | 2.00m | 3.88% |
| DWS Investments (UK) Ltd.as of 30 Jun 2024 | 1.78m | 3.47% |
| Engine Capital Management LPas of 30 Jun 2024 | 1.49m | 2.90% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
